Alexander A Vinks
Overview
Explore the profile of Alexander A Vinks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
214
Citations
3153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Samuels A, Irie K, Mizuno T, Reifenberg J, Punt N, Vinks A, et al.
Clin Transl Sci
. 2025 Feb;
18(2):e70086.
PMID: 39985779
The use of model-informed precision dosing to personalize infliximab has been shown to improve both the acquisition of concentration targets and clinical outcomes during maintenance. Current iterations of infliximab pharmacokinetic...
2.
Capal J, Ritter D, Franz D, Griffith M, Currans K, Kent B, et al.
Ann Child Neurol Soc
. 2024 Dec;
2(2):106-119.
PMID: 39726432
Objective: Tuberous sclerosis complex (TSC) results from overactivity of the mechanistic target of rapamycin (mTOR). Sirolimus and everolimus are mTOR inhibitors that treat most facets of TSC but are understudied...
3.
Pharmacokinetic Factors Associated With Early Meropenem Target Attainment in Pediatric Severe Sepsis
Paice K, Tang Girdwood S, Mizuno T, Pavia K, Punt N, Tang P, et al.
Pediatr Crit Care Med
. 2024 Aug;
25(12):1103-1116.
PMID: 39162600
Objectives: To determine the frequency of early meropenem concentration target attainment (TA) in critically ill children with severe sepsis; to explore clinical, therapeutic, and pharmacokinetic factors associated with TA; and...
4.
Pavia K, Tang Girdwood S, Paice K, Dong M, Mizuno T, Tang P, et al.
Pediatr Nephrol
. 2024 Aug;
40(2):513-521.
PMID: 39150525
Background: Elevated cefepime blood concentrations can cause neurotoxicity in adults. The consequences of elevated cefepime concentrations among pediatric patients are unknown. Future exploration of such effects requires first identifying patients...
5.
Wilson N, Tremblay S, Shields A, Woodle E, Alloway R, Vinks A, et al.
Transplant Direct
. 2024 Jul;
10(8):e1677.
PMID: 38988686
No abstract available.
6.
Sadaf A, Dong M, Pfeiffer A, Korpik J, Kalfa T, Latham T, et al.
Br J Haematol
. 2024 Jul;
205(3):1147-1158.
PMID: 38977270
The mechanisms of action of l-glutamine for the treatment of sickle cell disease (SCD) are not well understood and there are no validated clinical biomarkers to assess response. We conducted...
7.
van Hoogdalem M, Tanaka R, Johnson T, Vinks A, Mizuno T
Drug Metab Dispos
. 2024 May;
52(8):785-796.
PMID: 38769016
Sublingual buprenorphine is used for opioid use disorder and neonatal opioid withdrawal syndrome. The study aimed to develop a full physiologically based pharmacokinetic (PBPK) model that can adequately describe dose-...
8.
Hambrick H, Cervantes F, Dong M, Tang P, Arbough T, Vinks A, et al.
J Pediatr Pharmacol Ther
. 2024 Apr;
29(2):180-187.
PMID: 38596427
Ceftriaxone is used commonly for sepsis, including in children requiring continuous kidney replacement therapy (CKRT). No reports exist of pharmacokinetic (PK) parameters for children receiving ceftriaxone on CKRT. We enrolled...
9.
van Hoogdalem M, Tanaka R, Abduljalil K, Johnson T, Wexelblatt S, Akinbi H, et al.
Pharmaceutics
. 2024 Mar;
16(3).
PMID: 38543269
Buprenorphine readily crosses the placenta, and with greater prenatal exposure, neonatal opioid withdrawal syndrome (NOWS) likely grows more severe. Current dosing strategies can be further improved by tailoring doses to...
10.
Minar P, Colman R, Zhang N, Mizuno T, Vinks A
BMJ Open
. 2024 Mar;
14(3):e077193.
PMID: 38531570
Introduction: The only biologic therapy currently approved to treat moderate to severe Crohn's disease in children (<18 years old) are those that antagonise tumour necrosis factor-alpha (anti-TNF). Therefore, it is...